According to Glenmark Pharmaceuticals, the Russian Ministry of Healthcare has approved the company’s Momate Rhino mometasone furoate nasal spray for over-the-counter sales for the treatment of allergic rhinitis in adults.
Glenmark Pharmaceuticals Senior VP and Head,”Asia, Russia & CIS region, Csaba Kantor commented, “Glenmark has built strong capabilities in the area of respiratory and is among the leading players in this therapy in several markets globally. Russia is an important market for us and we are consistently looking to expand product offerings. We believe OTC is an interesting space and this approval for Momate Rhino nasal spray will help enhance our presence in this segment.”
VP and Business Head, Russia, Oxana Pozdnyakova added, “Allergic rhinitis affects a significant number of people in Russia. The approval to market Momate Rhino as an OTC product paves way for the company to widen patient accessibility of this medicine, which is particularly important at the start of the allergy season.”
Read the Glenmark Pharmaceuticals press release.
